Hepatitis C : Seniors face Medicare cost barrier for cancer meds

[Guest guest]

Hepatitis C : Seniors face Medicare cost barrier for cancer meds

Private insurance companies that deliver the Medicare prescription benefit say the problem is that drug makers charge too much for the medications, some of which were developed from taxpayer-funded research. The pharmaceutical industry faults insurers, saying copayments on drugs are higher than cost-sharing for other medical services, such as hospital care.Others blame the design of the Medicare prescription benefit itself, because it allows insurers to put expensive drugs on a so-called "specialty tier" with copayments equivalent to 25 percent or more of the cost of the medication.Drugs for multiple sclerosis, rheumatoid arthritis and hepatitis C also wind up on specialty tiers, along with the new anti-cancer pills. Medicare supplemental insurance — Medigap — doesn't cover those copayments. Read More

http://Hepatitis Cnewdrugs.blogspot.com/2011/06/hepatitis-c-seniors-face-medicare-cost.html